Cargando…
Health insurance system for hematologic diseases: what should we do?
Autores principales: | Jang, Moon Ju, Park, Hyeon Jin, Yoon, Sung-Soo, Lee, Je-Hwan, Park, Kyung-Duk, Kim, Seok-Jin, Im, Ho-Joon, Kim, Jin-Seok, Jang, Jun-Ho, Oh, Suk-Joong, Cho, Hee-Soon, Song, Jae-Woo, Lim, Yeon-Jung, Kim, Ho-Young |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065631/ https://www.ncbi.nlm.nih.gov/pubmed/21461295 http://dx.doi.org/10.5045/kjh.2011.46.1.6 |
Ejemplares similares
-
Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?
por: Cho, Won Kyung, et al.
Publicado: (2018) -
How Should We Assign Large Infiltrative Hepatocellular Carcinomas for Staging?
por: Lee, Yoo Jin, et al.
Publicado: (2020) -
What we should consider to facilitate recovery of the hematological profile in all patients after pancreaticoduodenectomy: the role of preoperative intravenous iron treatment
por: Kim, Eun Young, et al.
Publicado: (2023) -
Why should we monitor for hematologic adverse drug reactions to oxcarbazepine?
por: Jang, Gwang Cheon
Publicado: (2019) -
Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST?
por: Lee, Dong Ho, et al.
Publicado: (2021)